Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a Simple Preparation Method and Its Application for the Synthesis of a New Class of "activated" Sulfur-containing Cyclophosphamide (NSC-26271) Derivatives
Overview
Authors
Affiliations
4-Hydroperoxycyclophosphamide was obtained in approximately 20% yield by ozonization of cyclophosphamide in acetone/water at 0 degrees C. It was reduced to 4-hydroxycyclophosphamide, which was treated with several mercaptans to yield compounds of the type 4-(S-R)-mercapto-cyclophosphamide. In the solid state these compounds are stable at room temperature; in aqueous solution they are hydrolyzed to 4-hydroxycyclophosphamide or its tautomer, aldophosphamide. One of the 4-(S-R)-mercapto-cyclophosphamide compounds was tested biologically in vitro against Yoshida ascites tumor cells and showed the same cytotoxic activity as 4-hydroxycyclophosphamide.
Li G, Zhang S, Xue D, Feng Y, Li Y, Huang X J Pharm Anal. 2023; 13(3):262-275.
PMID: 37102105 PMC: 10123948. DOI: 10.1016/j.jpha.2023.02.001.
Wang J, Li G, Wang B, Han S, Sun X, Jiang Y J Exp Clin Cancer Res. 2019; 38(1):235.
PMID: 31164151 PMC: 6549289. DOI: 10.1186/s13046-019-1211-2.
Ifosfamide clinical pharmacokinetics.
Wagner T Clin Pharmacokinet. 1994; 26(6):439-56.
PMID: 8070218 DOI: 10.2165/00003088-199426060-00003.
Wagner T, Heydrich D, Voelcker G, HOHORST H J Cancer Res Clin Oncol. 1980; 96(1):79-92.
PMID: 7358774 DOI: 10.1007/BF00412899.
Wagner T, Heydrich D, Jork T, Voelcker G, HOHORST H J Cancer Res Clin Oncol. 1981; 100(1):95-104.
PMID: 7240346 DOI: 10.1007/BF00405906.